Close

Form 8-K Akili, Inc. For: Aug 18

August 19, 2022 5:29 PM EDT
NASDAQ false 0001850266 0001850266 2022-08-18 2022-08-18 0001850266 dei:FormerAddressMember 2022-08-18 2022-08-18

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 18, 2022

 

 

AKILI, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40558   98-1586159
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

 

125 Broad Street, Fifth Floor,

Boston MA

  02110
(Address of principal executive offices)   (Zip Code)

(617) 456-0597

(Registrant’s telephone number, including area code)

Social Capital Suvretta Holdings Corp. I

2850 W. Horizon Ridge Parkway, Suite 200

Henderson, NV 89052

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common stock, $0.0001 par value per share   DNAA   Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


Introductory Note.

On August 19, 2022, Social Capital Suvretta Holdings Corp. I (“SCS” and, after the Business Combination (as defined below), “Akili, Inc.”) consummated the transactions contemplated by its previously announced Agreement and Plan of Merger (the “Merger Agreement”), dated as of January 26, 2022, by and among SCS, Karibu Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of SCS, and Akili Interactive Labs, Inc., a Delaware corporation (“Akili”) (the “Business Combination”). As a result of the closing (the “Closing”) of the Business Combination, SCS’s name was changed to Akili, Inc.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Akili, Inc. 2022 Incentive Plan

On August 18, 2022, at an Extraordinary General Meeting (the “Extraordinary General Meeting”), shareholders of SCS approved by ordinary resolution and adopted the Akili, Inc. 2022 Incentive Plan (the “Incentive Plan”), which makes available for issuance 12,813,781 shares of common stock, par value $0.0001 per share, of Akili, Inc. (“Akili, Inc. common stock”). A summary of the Incentive Plan is included in SCS’s definitive proxy statement/prospectus for the Extraordinary General Meeting filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 21, 2022 (the “Definitive Proxy”) and is incorporated herein by reference, which summary is qualified in all respects by the full text of the Incentive Plan, which is attached as Annex G to the Definitive Proxy.

Akili, Inc. Employee Stock Purchase Plan

On August 18, 2022, at the Extraordinary General Meeting, shareholders of SCS approved by ordinary resolution and adopted the Akili, Inc. Employee Stock Purchase Plan (the “Employee Stock Purchase Plan”), which makes available for issuance 1,167,881 shares of Akili, Inc. common stock. A summary of the Employee Stock Purchase Plan is included in the Definitive Proxy and is incorporated herein by reference, which summary is qualified in all respects by the full text of the Employee Stock Purchase Plan, which is attached as Annex H to the Definitive Proxy.

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Extraordinary General Meeting, 28,713,054 SCS ordinary shares, which represented 90.04% of the ordinary shares outstanding and entitled to vote as of the record date for the Extraordinary General Meeting of July 14, 2022, were represented in person or by proxy. The final voting results for each matter submitted to a vote of the SCS shareholders at the Extraordinary General Meeting are set forth below.

Approval of the Business Combination Proposal

SCS shareholders approved by ordinary resolution and adopted the Merger Agreement and the Business Combination. A copy of the Merger Agreement is attached as Annex A to the Definitive Proxy and as Exhibit 2.1 to SCS’s Current Report on Form 8-K/A filed with the SEC on January 27, 2022 (the “Business Combination Proposal”). The voting results with respect to the Business Combination Proposal were as follows:

 

Votes For

 

Votes Against

 

Abstentions

27,637,348   1,069,282   6,424

Approval of the Domestication Proposal

SCS shareholders approved by special resolution a change of SCS’s jurisdiction of incorporation by deregistering as an exempted company in the Cayman Islands and continuing and domesticating as a corporation


incorporated under the laws of the State of Delaware. A copy of the form of Plan of Domestication and form of Certificate of Incorporation of Akili, Inc. are attached as Exhibit 2.2 to SCS’s Registration Statement on Form S-4/A filed with the SEC on April 4, 2022 and Exhibit 3.2 which is attached as Annex J to the Definitive Proxy (the “Domestication Proposal”). The voting results with respect to the Domestication Proposal were as follows:

 

Votes For

 

Votes Against

 

Abstentions

25,022,498   2,323,375   1,367,181

Approval of the Organizational Documents Proposal A

SCS shareholders approved by special resolution the change in the authorized share capital of SCS from 500,000,000 Class A ordinary shares, par value $0.0001 per share, 50,000,000 Class B ordinary shares, par value $0.0001 per share, and 5,000,000 preference shares, par value $0.0001 per share, to 1,000,000,000 shares of Akili, Inc. common stock, par value $0.0001 per share, and 100,000,000 shares of Akili, Inc. preferred stock, par value $0.0001 per share (“Organizational Documents Proposal A”). The voting results with respect to Organizational Documents Proposal A were as follows:

 

Votes For

 

Votes Against

 

Abstentions

25,020,510   2,324,986   1,367,558

Approval of Organizational Documents Proposal B

SCS shareholders approved by special resolution the issuance of any or all shares of Akili, Inc. preferred stock in one or more classes or series by the board of directors of Akili, Inc., with such terms and conditions as may be expressly determined by Akili, Inc.’s board of directors and as may be permitted by the Delaware General Corporation Law (“Organizational Documents Proposal B”). The voting results with respect to Organizational Documents Proposal B were as follows:

 

Votes For

 

Votes Against

 

Abstentions

24,698,312   2,647,561   1,367,181

Approval of Organizational Documents Proposal C

SCS shareholders approved by special resolution the adoption of the proposed Certificate of Incorporation and the proposed Bylaws, in the forms attached as Annex J and Annex K, respectively, to the Definitive Proxy, in connection with the consummation of the Business Combination, including (i) changing the corporate name from “Social Capital Suvretta Holdings Corp. I” to “Akili, Inc.,” (ii) making Akili, Inc.’s corporate existence perpetual, (iii) adopting Delaware as the exclusive forum for certain stockholder litigation and the United States Federal District Courts as the exclusive forum for litigation arising out of the Securities Act of 1933, as amended (the “Securities Act”), (iv) being subject to the provisions of Section 203 of Delaware General Corporation Law and (v) removing certain provisions related to SCS’s status as a blank check company that will no longer be applicable upon consummation of the Business Combination (“Organizational Documents Proposal C”). The voting results with respect to Organizational Documents Proposal C were as follows:

 

Votes For

 

Votes Against

 

Abstentions

25,022,502   2,323,375   1,367,177

Approval of the Director Appointment Proposals

SCS Class B shareholders approved by ordinary resolution the election of Bharatt Chowrira, J.D., Ph.D. and Kenneth Ehlert to serve as Class I directors, Christine Lemke and William “BJ” Jones, Jr. to serve as Class II directors and W. Edward Martucci, Ph.D., Chamath Palihapitiya and Adam Gazzaley, M.D., Ph.D. to serve as Class III directors, with Mr. Palihapitiya to serve as the Chairperson of the Akili, Inc. board of directors, who, upon the Closing, will be the directors of Akili, Inc.

 


The voting results with respect to the election of Bharatt Chowrira, J.D., Ph.D., were as follows:

 

Votes For

 

Votes Withheld

 

Abstentions

6,890,000   0   0

The voting results with respect to the election of Kenneth Ehlert were as follows:

 

Votes For

 

Votes Withheld

 

Abstentions

6,890,000   0   0

The voting results with respect to the election of Christine Lemke were as follows:

 

Votes For

 

Votes Withheld

 

Abstentions

6,890,000   0   0

The voting results with respect to the election of William “BJ” Jones, Jr. were as follows:

 

Votes For

 

Votes Withheld

 

Abstentions

6,890,000   0   0

The voting results with respect to the election of W. Edward Martucci, Ph.D. were as follows:

 

Votes For

 

Votes Withheld

 

Abstentions

6,890,000   0   0

The voting results with respect to the election of Chamath Palihapitiya were as follows:

 

Votes For

 

Votes Withheld

 

Abstentions

6,890,000   0   0

The voting results with respect to the election of Adam Gazzaley, M.D., Ph.D. were as follows:

 

Votes For

 

Votes Withheld

 

Abstentions

6,890,000   0   0

Approval of the Stock Issuance Proposal

SCS shareholders approved by ordinary resolution, for the purposes of complying with the applicable listing rules of the Nasdaq Capital Market, the issuance of Akili, Inc. common stock to (a) the investors (collectively, the “PIPE Investors”), pursuant to the subscription agreements (the “Subscription Agreements”) by and between SCS and the PIPE Investors, pursuant to which the PIPE Investors have subscribed for an aggregate of 16,200,000 shares of Akili, Inc. common stock for an aggregate purchase price of $162,000,000 (the “PIPE Investment”) and (b) the Akili stockholders pursuant to the Merger Agreement (collectively, the “Stock Issuance Proposal”). The voting results with respect to the Stock Issuance Proposal were as follows:

 

Votes For

 

Votes Against

 

Abstentions

25,020,988   2,324,885   1,367,181

Approval of the Incentive Plan Proposal

SCS shareholders approved by ordinary resolution the Incentive Plan (the “Incentive Plan Proposal”). The voting results with respect to the Incentive Plan Proposal were as follows:

 

Votes For

 

Votes Against

 

Abstentions

24,344,594   3,001,122   1,367,337

 


Approval of the Employee Stock Purchase Plan Proposal

SCS shareholders approved by ordinary resolution the Employee Stock Purchase Plan (the “Employee Stock Purchase Plan Proposal”). The voting results with respect to the Employee Stock Purchase Plan Proposal were as follows:

 

Votes For

  

Votes Against

  

Abstentions

25,020,314    2,325,559    1,367,181

Approval of the Auditor Ratification Proposal

SCS shareholders approved by ordinary resolution the ratification of the appointment by SCS’s audit committee of Marcum LLP as the independent registered public accountants to SCS to audit and report on SCS’s consolidated financial statements for the year ending December 31, 2022 (the “Auditor Ratification Proposal”). The voting results with respect to the Auditor Ratification Proposal were as follows:

 

Votes For

  

Votes Against

  

Abstentions

27,332,938    11,431    1,368,685

Approval of the Adjournment Proposal

SCS shareholders approved by ordinary resolution the adjournment of the Extraordinary General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there were insufficient votes for, or otherwise in connection with, the approval of one or more proposals at the Extraordinary General Meeting (the “Adjournment Proposal”). The voting results with respect to the Adjournment Proposal were as follows:

 

Votes For

  

Votes Against

  

Abstentions

24,686,758    2,665,536    1,360,760

Item 7.01 Regulation FD Disclosure.

On August 19, 2022, Akili, Inc. issued a press release announcing the Closing. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

24,772,478 of SCS’s Class A ordinary shares were presented for redemption in connection with the Business Combination.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following is furnished as an exhibit to this report:

 

Exhibit
No.

  

Description

99.1    Press Release dated August 19, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Akili, Inc.
By:  

/s/ W. Edward Martucci

  Name:     W. Edward Martucci
  Title:       Chief Executive Officer

Date:    August 19, 2022

Exhibit 99.1

 

LOGO

Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social

Capital Suvretta Holdings Corp. I

Akili, Inc. common stock to begin trading on Nasdaq under the ticker symbol “AKLI” on August 22, 2022

Total gross proceeds of more than $163 million will support launch of first FDA-cleared video game

treatment and advancement of late-stage pipeline

BOSTON, Mass. and PALO ALTO, Calif. – August 19, 2022 – Akili, a leading digital medicine company, today completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I (“SCS”) (Nasdaq: DNAA), a publicly traded special purpose acquisition company. The newly formed company, Akili, Inc. (“Akili”), is expected to start trading on The Nasdaq Capital Market (“Nasdaq”) under the new ticker symbol “AKLI” on August 22, 2022.

Akili raised more than $163 million from the transaction, before deducting transaction expenses and advisory fees, which, together with cash on hand, the company expects will be sufficient to fund at least 24 months of business operations, excluding any contributions from EndeavorRx® revenues. Proceeds from the transaction will fund the commercial launch of EndeavorRx, a first-of-its-kind, U.S. Food and Drug Administration (FDA) cleared and Conformité Européenne (CE) Mark certified prescription digital therapeutic for pediatric attention-deficit/hyperactivity disorder (ADHD) (see full indication and safety information below), as well as potential expansion into additional ADHD patient populations. Proceeds will also support the advancement of the company’s late-stage pipeline of product candidates designed to treat neuropsychiatric diseases, including autism spectrum disorder (ASD), multiple sclerosis (MS), and major depressive disorder (MDD). SCS shareholders approved the transaction at a general meeting on August 18, 2022.

Eddie Martucci, CEO of Akili, said: “Today’s milestone reflects the combined efforts of the committed Akili team and SCS who together made this defining moment possible. Millions of people worldwide live with cognitive impairment without effective treatments. I am proud of our talented employees – leaders in neuroscience, entertainment and consumer technology – who are propelling Akili’s innovative software-based therapeutics forward to deliver an engaging, immersive experience. I am extremely excited about what’s ahead as we begin to scale and serve patients in need.”

Chamath Palihapitiya, Chairman and CEO of SCS, commented: “With this milestone completed, Akili has a number of others ahead, including its upcoming commercial launch of EndeavorRx and a strong clinical pipeline of breakthrough digital therapeutic candidates that have the potential to treat a host of cognitive impairments. I look forward to working with Eddie and the Akili team as they enter this new and exciting chapter.”


LOGO

A commercial-stage company, Akili develops digital therapeutics that combine science and technology to address cognitive impairments in patients, representing a new category of software-based medicine that is designed to directly target brain function and is delivered through engaging consumer entertainment. Cognitive impairments – including inattention, poor concentration, memory loss, difficulties learning new skills, and difficulties with decision making – are in aggregate among the largest unmet medical needs and are increasingly recognized as contributing to or associated with dozens of chronic diseases and acute illnesses.

Scheduled for U.S. launch in the fourth quarter of 2022, EndeavorRx is the first-ever prescription video game and the first-ever FDA-cleared digital therapeutic indicated to improve attention function in children with ADHD (see full indication below). In addition, the company’s patented and clinically validated Selective Stimulus Management Engine (SSMETM) has demonstrated proof-of-concept efficacy in controlled trials targeting attention and cognitive dysfunction in ASD, MS, and MDD.

Akili CEO and co-founder Eddie Martucci will continue to lead Akili’s management team and serve on Akili’s board. Chamath Palihapitiya, Chairman and CEO of SCS, will chair Akili’s board. Akili’s board also includes William (“BJ”) Jones, Jr., Chief Commercial Officer of Biohaven Pharmaceuticals Holding Company Ltd.; Christine Lemke, Co-Chief Executive Officer and Director of Evidation Health, Inc.; Kenneth Ehlert, former Chief Scientific Officer of UnitedHealth Group; Bharatt Chowrira, Ph.D., J.D., president of PureTech Health plc.; and Adam Gazzaley, M.D., Ph.D., Akili co-founder, David Dolby Distinguished Professor of Neurology, Physiology, and Psychiatry and the Founder & Executive Director of Neuroscape at the University of California, San Francisco.

Advisors

Morgan Stanley & Co. LLC (“Morgan Stanley”) and Cowen and Company, LLC (“Cowen”) served as financial advisors to Akili. Morgan Stanley, Credit Suisse, and Cowen served as co-placement agents to SCS with respect to the portion of the PIPE financing raised from non-insider qualified institutional buyers and institutional accredited investors. Morgan Stanley, Credit Suisse, and Cowen did not act as agents or participate in any role with respect to, and did not earn any fees from, the portion of the PIPE financing raised from insiders and individual investors. Credit Suisse and Cowen served as capital markets advisors to Akili. BofA Securities, Inc. served as capital markets advisor to SCS. Goodwin Procter LLP served as legal counsel to Akili. Wachtell, Lipton, Rosen & Katz served as legal counsel to SCS. Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to the PIPE placement agents.

EndeavorRx Indication and Overview

EndeavorRx is the first-and-only FDA-cleared treatment delivered through a video game experience. EndeavorRx is indicated to improve attention function as measured by computer-based testing in children ages 8 to 12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure Test of Variables of Attention (TOVA®) of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use


LOGO

as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. EndeavorRx is available by prescription only. It is not intended to be used as a stand-alone therapeutic and is not a substitution for a child’s medication. The most common side effect observed in children in EndeavorRx’s clinical trials was a feeling of frustration, as the game can be quite challenging at times. No serious adverse events were associated with its use. EndeavorRx is recommended to be used for approximately 25 minutes a day, 5 days a week, over initially at least 4 consecutive weeks, or as recommended by your child’s health care provider. To learn more about EndeavorRx, please visit EndeavorRx.com.

About Akili

Akili is pioneering the development of cognitive treatments through game-changing technologies. Our approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device but experienced like entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.

About Social Capital Suvretta Holdings Corp. I

Social Capital Suvretta Holdings Corp. I was led by Chamath Palihapitiya and Kishen Mehta and was a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was focused on businesses operating in the biotechnology industry and within the neurology subsector. To learn more about Social Capital Suvretta Holdings, visit https://www.socialcapitalsuvrettaholdings.com/.

Forward-Looking Statements

This communication may contain certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding Akili’s expectations for EndeavorRx and digital medicine, the development of its platform and advancement of late-stage pipeline product candidates designed to treat neuropsychiatric diseases, including ASD, MS) and MDD, expectations and timing regarding the commercial launch of EndeavorRx and plans for the potential expansion of EndeavorRx into additional ADHD populations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Akili to successfully commercialize EndeavorRx and


LOGO

continue to advance its clinical development pipeline, (ii) the ability to recognize the anticipated benefits of the proposed transaction, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees, (iii) the evolution of the markets in which Akili competes, (iv) the ability of Akili to defend its intellectual property and satisfy regulatory requirements, (v) the impact of the COVID-19 pandemic on Akili’s business, (vi) Akili’s expectations regarding its market opportunities, (vii) the risk of downturns and a changing regulatory landscape in the highly competitive industry in which Akili operates and (viii) the timing and results expected from Akili and its partners’ clinical trials. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties proxy statement/prospectus filed with the SEC on July 21, 2022, under the heading “Risk Factors,” and other documents that SCS filed or Akili has filed or will file, with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Akili assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Akili gives no assurance that it will achieve its expectations.

###

Contacts

Akili

Julie DiCarlo

[email protected]

Social Capital Suvretta

Reze Wong

[email protected]

FGS Global

[email protected]



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings